Grant of Options and Director Dealing

Molecule Group PLC

21 October 2026

 

Molecule Group plc

(the "Company", "Group" or "Molecule")

Grant of Options and Director Dealing

Molecule Group plc, the Company building a leading regulated UK ePharmacy through buy-and-build, announces that on 21 October 2026 the Company granted Susan Clement Davies, the Company's Chair and Non-Executive Director, 47,619 options ("Options") over ordinary shares of 10 pence each in the Company ("Ordinary Shares"). The Options will vest over 5 years, with 40% vesting on the second anniversary of grant and the remaining 60% vesting in equal instalments on the third, fourth and fifth anniversaries of grant. The Options are exercisable at a price of £2.10 per Ordinary Share.

The Notification of Dealing is set out below. This notification is issued in accordance with Article 19.3 of the UK Market Abuse Regulation.

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name:	Susan Clement Davies
2	Reason for the notification
a)	Position/Status:	Chair and Non-Executive Director
b)	Initial Notification/Amendment:	Initial Notification
3	Details of the issuer, emission allowance market participation, auction platform, auctioneer or auction monitor
a)	Name:	Molecule Group plc
b)	LEI:	213800W5TPGBRC2V7L20
4.	Details of transaction(s); section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted.
a)	Description of the financial instrument:	Ordinary Shares of 10 pence each
b)	Identification code:	ISIN: GB00BTQLZH16
b)	Nature of the transaction:	Award of options over Ordinary Shares
c)	Price(s) and volume(s):	Price Volume Nil 47,619
d)	Aggregated volume: Price:	Single Transaction
e)	Date of the Transaction:	21-10-2026
f)	Place of the Transaction:	Outside a trading venue

For further information please contact:

Molecule Group plc Michael Kraftman, Chief Executive Officer Keith Butcher, Chief Financial Officer Brendan O'Brien, Chief Operating Officer investors.molecule.co.uk	Email: [e-mail]
Canaccord Genuity Limited (Nominated Adviser and Sole Broker) Simon Bridges / Harry Pardoe / Elizabeth Halley-Stott	Tel: [phone]
Alma Strategic Communications (Financial PR) Justine James / Sam Modlin / Will Merison	Email: [e-mail] Tel: [phone]

Notes to Editors

Molecule Group plc (AIM: MOL) is building a leading regulated ePharmacy platform, through its disciplined buy-and-build strategy. Following the acquisitions of CloudRx, Webmed and Hyperdrug in March 2026, the Group has established a diversified, profitable platform spanning B2B prescription fulfilment and B2C digital pharmacy services, with a high proportion of recurring revenues and strong cash generation. Future growth is expected to be supported through the acquisition of complementary businesses, expansion into new sectors or markets, and investment in long-term assets.

The Group is led by an experienced management team with deep healthcare, eCommerce and buy-and-build expertise. For more information, visit investors.molecule.co.uk

 

END